Start the conversation
As the longtime subscribers among you folks know, we love spin-offs here at Private Briefing.
These corporate breakups are a way to make market-beating returns - and at below-market risk.
It's that penchant for spin-offs that prompted our pre-breakup recommendation of Abbott Laboratories Inc. (NYSE: ABT) back in June 2012.
This is premium content for Private Briefing subscribers only.